Transgene SA
TRGNF
$0.70
-$0.89-55.98%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 37.90K | 656.50K | 1.28M | 1.91M | 2.53M |
| Total Other Revenue | 6.83M | 6.31M | 5.74M | 6.53M | 7.26M |
| Total Revenue | 6.87M | 6.96M | 7.02M | 7.81M | 8.54M |
| Cost of Revenue | 37.09M | 34.58M | 31.85M | 32.02M | 32.00M |
| Gross Profit | -30.21M | -27.62M | -24.82M | -24.21M | -23.46M |
| SG&A Expenses | 8.39M | 8.70M | 8.97M | 8.29M | 7.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -33.30K | -52.70K | -73.40K | 690.50K | 1.44M |
| Total Operating Expenses | 45.45M | 43.23M | 40.75M | 41.00M | 41.00M |
| Operating Income | -38.57M | -36.26M | -33.72M | -33.19M | -32.46M |
| Income Before Tax | -36.75M | -30.89M | -24.78M | -24.56M | -24.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.75 | -30.89 | -24.78 | -24.56 | -24.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.75M | -30.89M | -24.78M | -24.56M | -24.14M |
| EBIT | -38.57M | -36.26M | -33.72M | -33.19M | -32.46M |
| EBITDA | -37.19M | -34.95M | -32.50M | -31.72M | -30.76M |
| EPS Basic | -0.32 | -0.28 | -0.25 | -0.24 | -0.24 |
| Normalized Basic EPS | -0.20 | -0.18 | -0.15 | -0.15 | -0.15 |
| EPS Diluted | -0.32 | -0.28 | -0.25 | -0.24 | -0.24 |
| Normalized Diluted EPS | -0.20 | -0.18 | -0.15 | -0.15 | -0.15 |
| Average Basic Shares Outstanding | 466.67M | 435.67M | 404.68M | 403.52M | 402.36M |
| Average Diluted Shares Outstanding | 466.67M | 435.67M | 404.68M | 403.52M | 402.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |